Amgen To Extend Enbrel Cancer, Autoimmune Safety Study By Five Years
This article was originally published in The Pink Sheet Daily
Executive Summary
The company satisfied a prior post-marketing commitment to collect five-year data on cancer and autoimmune disease development but will now extend that follow-up period to a total of 10 years, an FDA approval letter for labeling revisions to the TNF inhibitor says.